Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BalanceD-CKD
jRCT2031260364Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in chronic kidney disease (CKD) comparing Balcinrenone/dapagliflozin with Dapagliflozin (2 arms). Primary endpoint: Primary composite endpoint. Started Sep 2026; status: recruiting.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031260364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260364.